CSTL — Castle Biosciences Cashflow Statement
0.000.00%
Last trade - 00:00- $595.07m
- $312.38m
- $332.07m
- 95
- 55
- 46
- 72
Annual cashflow statement for Castle Biosciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -10.3 | -31.3 | -67.1 | -57.5 | 18.2 |
| Depreciation | |||||
| Amortisation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 10.5 | 21.7 | 16.8 | 46.4 | 43.3 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 9.15 | -4.1 | -0.007 | -6.63 | -14.1 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | 9.87 | -19 | -41.7 | -5.63 | 64.9 |
| Capital Expenditures | -4.75 | -3.48 | -5.63 | -13.6 | -28.3 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0.003 | -63.2 | -161 | -2.56 | -21.8 |
| Acquisition of Business | |||||
| Sale of Business | |||||
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -4.75 | -66.7 | -167 | -16.2 | -50.1 |
| Financing Cash Flow Items | 1.61 | 1.2 | 0.804 | -2.42 | -5.78 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 306 | 5.42 | 1.51 | -2.3 | 6.14 |
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 311 | -80.2 | -207 | -24.1 | 20.9 |